Endexx Q3 Year-Over-Year Quarterly Sales Increase 246%
Endexx Corporation (OTC: EDXC) announced significant growth in its fiscal third quarter ending June 30, 2022, reporting revenues of $418,151, a remarkable 246% increase compared to $120,801 in Q3 2021. Over nine months, revenues surged 127% to $947,428 from $416,094 year-over-year. The company emphasizes its presence in 8,000 retail locations and its position as a top seller of CBD products in national pharmacies. However, the financial results were impacted by a non-cash derivative liability linked to trading irregularities. Future growth is anticipated as market conditions evolve.
- Revenues increased by 246%, reaching $418,151 in Q3 2022 compared to $120,801 in Q3 2021.
- Nine-month revenues rose 127%, totaling $947,428 versus $416,094 in the same period of 2021.
- Presence in 8,000 retail stores, including major national pharmacies, supports long-term growth.
- A non-cash derivative liability recorded in Q3 financials due to trading irregularities.
Endexx Announces Fiscal Third Quarter 2022
CAVE CREEK, AZ, Aug. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Endexx Corporation (OTC: EDXC), a provider of innovative plant based and sustainable health and skincare products now available in 8,000 Mass Retail and Pharmacy stores nationwide, today announced its Form 10Q, third quarter ending June 30, 2022. Endexx continues to rebound and show growth in mass retail sales. The 8000 mass retail stores are in the early stages of growth and are anticipated to fluctuate and grow over the remainder of fiscal 2022 and accelerate in 2023 and 2024 respectively. Endexx reported
“The third quarter showed continued expansion in revenues in Mass Retail stores. We currently are in the top two National Pharmacies and the largest premium Mass Retailer in the US,” stated CEO Todd Davis. Davis added, “Opening orders in mass retail is the beginning of long-term sales cycles, expansion requires investment and Endexx has managed the challenges of this growth cycle as efficiently as possible given the current financial markets.” Davis concluded, “With ongoing anticipation of Federal Regulatory advances, we believe this industry is still in its infancy and has the potential to become a leading multi-billion dollar growth industry in the next few years. According to Nielsen Ratings, Endexx's topical balm and topical cream are the Top Two selling CBD topical products in the pain aisle in Nationwide Pharmacies.”
Recorded in Q3 financials is an extraordinary non-cash derivative liability. This is due to the Double Diamond trading in April that allowed below market trading prices to be posted in time and sales records in quotation services. Endexx is working to correct the condition that created the non-cash derivative loss.
See 10Q filing at:
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001109486/000149315222022763/form10-q.htm
Learn more about Endexx at:
www.endexx.com & www.cbdunlimited.com
To find Endexx products visit:
Visit www.target.com and search for Blesswell or, https://www.target.com/s?searchTerm=blesswell&stof=true
Endexx highly recommends our customers and stakeholders to discover the value and experience our Blesswell™ Skincare products. Visit www.BlesswellSkincare.com to learn more.
Try the top 2 selling products in the pain aisle
https://www.walgreens.com/search/results.jsp?Ntt=CBD%20Unlimited
Go to high performance Men’s Grooming Products at:
https://www.cvs.com/shop/brand-shop/b/blesswell
For a store located near you, visit websites below.
For more information about Endexx Corporation:
Visit: www.endexx.com , www.cbdunlimited.com , www.maggiesline.com , www.blesswell.co and www.blesswellskincare.com
About Endexx Corporation
Endexx Corporation, develops and distributes all-natural plant-derived topical skincare products. Its products vary from balms, creams, lotions, butters, masks, scrubs and oils all with the shared purpose of healthy skin and grooming wellness. The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and the support of skin health.
Safe Harbor Notice
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.
Contact:
For further investor and media information, contact:
Endexx Corporation
Todd Davis
Chairman & CEO
Endexx@endexx.com
480-595-6900
Attachment
FAQ
What were Endexx's financial results for the third quarter of 2022?
How much revenue did Endexx generate in the first three quarters of 2022?
What challenges did Endexx face in its latest financial report?
In how many retail locations are Endexx products available?
What is Endexx's position in the CBD product market?
